Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19

Sponsor
Codagenix, Inc (Industry)
Overall Status
Completed
CT.gov ID
NCT04619628
Collaborator
(none)
48
1
7
17.6
2.7

Study Details

Study Description

Brief Summary

This is the first study of COVI-VAC in humans. The purpose of the study is to evaluate the safety and immune response of COVI-VAC (a live attenuated vaccine to prevent COVID-19) in healthy adults aged 18 to 30 years. Approximately 48 participants will be enrolled into 1 of 3 dose groups (low, medium, high). Within each of these dose groups, participants will be assigned randomly to receive either 2 doses of COVI-VAC 28 days apart, 2 doses of placebo (saline), or 1 dose of COVI-VAC and 1 dose of placebo. COVI-VAC or placebo is administered by drops into each nostril. Neither the participants nor the researchers will know whether COVI-VAC or placebo has been received.

To assess the safety of the vaccine, each participant will record symptoms and oral temperature in a diary daily for 14 days after each dose. Safety laboratory tests, physical exams, ECGs, and a chest X-ray will also be performed, and peak expiratory flow and vital signs will be measured. Adverse events and medication use will be recorded.

Blood samples and intranasal samples will be collected to assess the immune response from the vaccine.

Condition or Disease Intervention/Treatment Phase
  • Biological: COVI-VAC
  • Other: Placebo
Phase 1

Study Design

Study Type:
Interventional
Actual Enrollment :
48 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
First-in-human, Randomised, Double-blind, Placebo-controlled, Dose-escalation Study in Healthy Young Adults Evaluating the Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Candidate for Prevention of COVID-19
Actual Study Start Date :
Dec 11, 2020
Actual Primary Completion Date :
Jun 26, 2021
Actual Study Completion Date :
May 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Saline

Normal saline

Other: Placebo
normal saline

Experimental: Low dose cohort 1

COVI-VAC, single dose

Biological: COVI-VAC
intranasal, live attenuated vaccine against SARS-CoV-2

Experimental: Medium dose cohort 1

COVI-VAC, single dose

Biological: COVI-VAC
intranasal, live attenuated vaccine against SARS-CoV-2

Experimental: High dose cohort 1

COVI-VAC, single dose

Biological: COVI-VAC
intranasal, live attenuated vaccine against SARS-CoV-2

Experimental: Low dose cohort 2

COVI-VAC, two doses 28 days apart

Biological: COVI-VAC
intranasal, live attenuated vaccine against SARS-CoV-2

Experimental: Medium dose cohort 2

COVI-VAC, two doses 28 days apart

Biological: COVI-VAC
intranasal, live attenuated vaccine against SARS-CoV-2

Experimental: High dose cohort 2

COVI-VAC, two doses 28 days apart

Biological: COVI-VAC
intranasal, live attenuated vaccine against SARS-CoV-2

Outcome Measures

Primary Outcome Measures

  1. Reactogenicity [14 days after each dose]

    Percentage of subjects with reactogenicity events

  2. Adverse events [Days 1 through 57]

    Percentage of subjects with adverse events

  3. Serious adverse events [Days 1-400]

    Percentage of subjects with serious adverse events

Secondary Outcome Measures

  1. IgG titre [Days 1, 15, 29, 43, 57, 120, 210, and 400]

    IgG titre measured by ELISA in serum collected on Days 1, 15, 29, 43, 57, 120, 210, and 400

  2. Neutralizing antibody titre [Days 1, 15, 29, 43, 57, 120, 210, and 400]

    Neutralising antibody level measured by microneutralisation assay in serum

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 30 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Subjects who meet all of the following criteria may be included in the study:
  1. Men and women aged between 18 to 30 years of age, inclusive, on the day of signing the informed consent form (ICF)

  2. In good health with no history, or current evidence, of clinically significant medical conditions with particular reference to, but not restricted to, hypertension, diabetes, thromboembolic disorders, coronary heart disease, chronic obstructive lung disease, and no clinically significant test abnormalities that will interfere with subject safety, as defined by medical history, physical examination, vital signs (including oxygen saturation), ECG, spirometry, and safety laboratory tests as determined by the Investigator

  3. Total body weight of greater or equal to 50 kg and body mass index (BMI) greater or equal to 18.0 kg/m2 and less than or equal to 28.0 kg/m2 (the upper limit of the BMI may be increased to less than or equal to 30 kg/m2 at the Investigator's discretion in case of a muscular healthy subject for whom BMI may be biased upwards)

  4. Negative drugs of abuse, cotinine, and alcohol screen (unless explained by prescribed medication)

  5. Negative pregnancy test for women who have not been surgically sterilised

  6. Negative COVID Clear test

Exclusion Criteria:
Subjects who meet any of the following criteria will be excluded from the study:
  1. Haemoglobin A1c ≥6.0% or 42 mmol/mol

  2. Forced expiratory volume in 1 second (FEV1) less than 80% predicted value

  3. Signs or symptoms suggestive of upper or lower respiratory tract infection (including fever or persistent cough) within 28 days of Day 1

  4. Pregnant, possibly pregnant, or lactating women

  5. Women who have been pregnant through the third trimester or given birth within the past 6 months

  6. Planning a pregnancy (subject or partner) within 90 days after the last IMP dose

  7. Inadequate venous access for repeated phlebotomy

  8. History of confirmed or suspected SARS-CoV-2 infection

  9. Contact with any individual subsequently confirmed to have SARS-CoV-2 within 14 days after contact

  10. History of wheeze treated with inhaler(s)

  11. Respiratory symptoms, including wheeze, that have ever resulted in hospitalisation

  12. Known bronchial hyperreactivity to viruses

  13. Any significant abnormality altering the anatomy of the nose in a substantial way or nasopharynx that may interfere with the aims of the study and in particular any of the nasal assessments or viral challenge (historical nasal polyps can be included, but large nasal polyps causing current and significant symptoms and/or requiring regular treatments in the last month are excluded)

Contacts and Locations

Locations

Site City State Country Postal Code
1 hVIVO London United Kingdom E1 2AX

Sponsors and Collaborators

  • Codagenix, Inc

Investigators

  • Principal Investigator: Daryl Bendel, MD, Hvivo

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Codagenix, Inc
ClinicalTrials.gov Identifier:
NCT04619628
Other Study ID Numbers:
  • CDX-CoV-001
First Posted:
Nov 6, 2020
Last Update Posted:
Jun 28, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Codagenix, Inc
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 28, 2022